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Objective: To investigate cytokine gene expression in patients with aortic valve stenosis (AS) and with
idiopathic dilated cardiomyopathy (DCM), and to correlate wall stress with myocardial proinflammatory
cytokine gene expression.
Methods: Human left ventricular (LV) myocardial biopsies were obtained for subsequent reverse
transcription polymerase chain reaction of tumour necrosis factor a (TNFa), interleukin (IL) -1b, and IL-6
mRNA. The study population consisted of 24 patients with AS and 10 patients with idiopathic DCM.
Results: Patients with AS had a larger ejection fraction (56 (5) v 37 (4)%, p , 0.01), smaller LV end
diastolic volumes (146 (11) v 267 (21) ml, p , 0.01), and lower end systolic wall stress (44 (7) v 112
(11) kdyn/cm2, p , 0.001). Upregulation of TNFa, IL-1b, and IL-6 gene expression was detected in both
groups. However, TNFa gene expression was significantly higher in AS than in DCM (p = 0.009). No
correlation was found between haemodynamic parameters and TNFa gene expression. In patients with AS
there was a strong inverse relation between circulating TNFa and TNFa gene expression (r = 20.685,
p = 0.014), between circulating TNFa and IL-1b gene expression (r = 20.664, p = 0.018), and
between soluble TNF receptor 2 and TNFa gene expression (r = 20.685, p = 0.020). Myocardial gene
expression of TNFa was significantly higher in patients with well compensated AS than in patients with
decompensated AS (p = 0.017). Similarly, patients with decompensated DCM were characterised by
significantly lower TNFa gene expression than were patients with well compensated DCM (p = 0.011).
Conclusion: TNFa gene expression is significantly higher in patients with pressure overload than in normal
hearts, in patients with idiopathic DCM, and in patients with compensated versus decompensated heart
failure. Secondly, in patients with AS proinflammatory cytokine gene expression did not affect systolic
performance. The higher TNFa gene expression in patients with compensated heart failure suggests that
cytokine gene expression has an adaptive role in the early phase of LV remodelling.
T
here is substantial evidence that myocardial cytokines
such as tumour necrosis factor a (TNFa), interleukin (IL)
-6,1 and IL-1b2 are generated after sustained haemody-
namic overloading of the heart, whether it results from
pressure3 or volume overload. Accordingly TNFa gene
expression is upregulated in the ventricles of humans with
idiopathic dilated and ischaemic cardiomyopathy.4 In these
patients circulating TNFa protein concentrations correlate
with the severity of the disease.5 Cytokines negatively affect
cardiac contractility by modulating intracellular calcium
fluxes during systole6 by inducing nitric oxide synthase,
which can generate peroxynitrite in the presence of excess
free radicals7 and by mediating apoptosis.8 9
The origin of these cytokines remains a matter of debate.
Observational work has provided proof for endotoxin induced
immune activation10 11 as well as for myocardial cytokine
production.4 12 Under experimental conditions such as
volume overload or passive muscle stretch, the myocardium
generates biologically active TNFa13 and it has recently been
shown that transaortic constriction results in myocardial
upregulation of IL-1b, IL-6, and TNFa gene expression and
their respective receptors.14 In addition unloading of the
terminally failing heart by venting13 or by prolonged
mechanical circulatory support15 results in a downregulation
of myocardial TNFa gene expression.16 Taken together these
data suggest that haemodynamic factors such as wall stress
have a major role in the enhanced myocardial expression of
relevant myocardial mediators such as cytokines.
Nevertheless, recent clinical work showed that in transplant
recipients with normal systolic function, without any
histological evidence of rejection and without any arguments
for pressure or volume overload, cytokine gene expression
may be upregulated 10-fold to 100-fold higher than in
patients with dilated cardiomyopathy (DCM).17 Furthermore,
Clark and colleagues18 reported that the fall in serum TNFa
and IL-6 concentrations observed after ventricular unloading
was only temporary and that cytokine concentrations
returned to preoperative concentrations at day 90. These
observations suggest that factors other than haemodynamic
load may interfere with cytokine gene expression.
Because of these conflicting data, the present study was set
up to investigate the stimulus for expression of TNFa, IL-1b,
and IL-6 in a human setting and to correlate myocardial gene
expression with haemodynamic parameters of left ventricular
(LV) contractile performance and circulating cytokine con-
centrations. Therefore, LV endomyocardial biopsies were
procured at the time of diagnostic cardiac catheterisation or
at surgery from patients with pressure overload cardiomyo-
pathy caused by symptomatic aortic valve stenosis (AS) and
from patients with idiopathic DCM.
Abbreviations: AS, aortic valve stenosis; DCM, dilated
cardiomyopathy; ELISA, enzyme linked immunosorbent assay; IL,
interleukin; LV, left ventricular; LVID, left ventricular internal dimension;
PCR, polymerase chain reaction; PWT, posterior wall thickness; RT,
reverse transcription; sTNFR, soluble tumour necrosis factor receptor;
TNFa, tumour necrosis factor a
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METHODS
Study population
Thirty four patients in stable condition (20 men, mean (SD)
age 66 (11) years) with moderate to severe heart failure19
caused by idiopathic DCM (n = 10) and symptomatic AS
(n = 24) referred for elective right left heart catheterisation
were selected for the study. All patients provided informed
consent and the protocol was approved by the local ethics
committee. Idiopathic DCM was diagnosed on the basis of a
normal coronary angiogram and evidence of abnormal LV
function by means of contrast ventriculography (LV ejection
fraction (LVEF) , 45% or indexed LV end diastolic volume
. 102 ml/m2).20 Histological evaluation excluded an inflam-
matory cause of the DCM. The patients with AS were
characterised by an LVEF . 50% and normal epicardial
coronary arteries. AS was caused by degenerative aortic valve
disease. Twelve patients with AS presented with effort
induced syncope, six with exertional dyspnoea, and six with
a history of angina. Patients with ischaemic heart disease or
atrial fibrillation were excluded.
Cardiac catheterisation
The left and right sides of the heart were catheterised from
the right femoral artery and vein. Right atrial pressure,
pulmonary artery pressure, pulmonary capillary wedge
pressure, and cardiac output were measured by use of a
Swan-Ganz catheter. LV pressure was recorded with a
catheter positioned in the LV cavity. LV angiograms
were obtained in the right and left anterior oblique
positions. Mean gradient across the aortic valve was
measured and aortic valve area was calculated with the
Gorlin formula.21
LV endomyocardial biopsies were procured during aortic
valve replacement from patients with AS, whereas in patients
with idiopathic DCM LV endomyocardial biopsies were
obtained at the end of the diagnostic left to right heart
catheterisation. All biopsies were procured at the level of the
distal interventricular septum. They were immediately frozen
in liquid nitrogen and stored at 280 C˚ for subsequent
detection of cytokine mRNA by reverse transcription (RT)
polymerase chain reaction (PCR). In patients with DCM a
histological diagnosis of myocarditis was excluded by
routine endomyocardial biopsy. In patients with AS
biopsies were procured immediately after the start of
the pump run following excision of the stenotic aortic
valve to avoid extracorporeal circulation mediated cytokine
induction. As a control endomyocardial biopsies were
obtained from four donor hearts at the time of transplanta-
tion. The mean (SD) age of the donors was 39 (3) years and
there were three men and one woman. None of the donor
hearts had ischaemic heart disease and the mean LVEF was
65 (12)%.
Echocardiographic analysis
LV meridional wall stress was estimated from M mode data
in combination with pressure data, by the formula: wall
stress = 0.334 6 LV pressure 6 LVID/[PWT 6 (1 + PWT/
LVID)], where PWT is posterior wall thickness and LVID the
LV internal dimension.22 This was technically possible in 30
patients (10 DCM, 20 patients with AS) whereas the
echocardiographic image quality was insufficient in four
patients. Patients with AS were considered to have adequate
compensation when end systolic wall stress was , 90 kdyn/
cm2. When end systolic wall stress was > 90 kdyn/cm2 they
were considered to have decompensated heart failure.23
Similarly patients with DCM with LV end diastolic pressure
. 16 mm Hg were considered to have decompensated heart
failure and reduced preload reserve.20
Cytokine protein plasma concentrations
In the patients with AS, plasma concentrations of TNFa, IL-6,
soluble TNF receptor (sTNFR) 1, and sTNFR2 were sampled
at the time of LV endomyocardial biopsy. Plasma concentra-
tions were determined by a high sensitivity, commercially
available enzyme linked immunosorbent assay (ELISA) kit
(R&D Systems Inc, Minneapolis, Minnesota, USA). These
assays have a high sensitivity with a lower limit of detection
of 4.4 pg/ml for TNFa, 1.5 pg/ml for IL-6, 0.43 pg/ml for
sTNFR1, and , 1 pg/ml for sTNFR2 with interassay and
intra-assay variabilities lower than 7% according to the
manufacturer. Plasma samples obtained from 10 age
matched volunteers (mean age 55 (9) years) without
evidence of systemic or cardiovascular disease were assayed
to determine the reference plasma cytokine concentration.
Myocardial cytokine gene expression
Because of the small size of the human heart tissue samples,
a highly sensitive RT-PCR method was developed for cytokine
mRNA quantification. As described previously in detail, this
method allows quantification of tissue samples as low as 2–
3 mg.24 The tissue samples were fresh frozen in liquid
nitrogen and stored at 280 C˚. The frozen samples were
thawed in 1 ml of Trizol solution and homogenised in a
Polytron 3000 homogeniser at 30 000 rpm for 30 seconds.
The total RNA was extracted and stored at 280 C˚ according
to the manufacturer’s protocol. Poly(A) RNA from the total
RNA was captured with biotin labelled oligo-(dT) 20
according to the manufacturer’s protocol and immobilised
by transferring the captured RNA to streptavidin coated
microfuge tubes (mRNA Capture Kit, Roche Molecular
Biochemicals, USA). After immobilisation the tubes were
washed three times and stored at 280 C˚. First strand cDNA
was synthesised directly on the immobilised poly(A) RNA
according to the manufacturer’s protocol (1st Strand cDNA
Synthesis Kit for RT-PCR, Roche Molecular Biochemicals).
PCR primer design and selection
PCR primers were designed so that there was no comple-
mentarity between the sense and antisense strands, thus
avoiding the formation of primer dimers. Additionally, PCR
sense and antisense primers were designed in such a way
that they were positioned either on the intron-exon junction
or on the exons of the respective target genes. With these
criteria, the PCR primers for various oligonucleotides were
designed with the DataMinder 3.2 computer program. To
generate copy number cDNA standards, cDNA clones encod-
ing the target genes for various cytokines and b actin were
obtained (table 1).
Cytokine quantification
The numbers of mRNA copies for TNFa, IL-6, and IL-1b were
determined by use of real time quantitative RT-PCR
LightCycler technology. Because of the low quantity of the
biopsy samples, b actin mRNA copy numbers were used to
normalise the cytokine mRNA samples. The data are
presented as copies of cytokine transcripts per 106 copies of
b actin.
Statistical analysis
Parametric data are expressed as mean (SD). Student’s t test,
a Mann-Whitney test, and a Spearman correlation coefficient
were used for appropriate comparisons. A stepwise multiple
regression analysis was used for multivariate re-evaluation of
univariate correlations. Variables were the following: wall
stress, aortic valve area, mean aortic gradient, LV end
diastolic pressure, and LVEF. Significance was set at a two
tailed probability level of p , 0.05.
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RESULTS
Baseline characteristics
Table 2 reports clinical characteristics and table 3 reports
echocardiographic and haemodynamic data.
Patients with AS were older (p = 0.001) and were
characterised by higher LVEF (p = 0.013) and smaller LV
end diastolic (p , 0.001) and end systolic volumes
(p = 0.005) than patients with DCM, despite similar
pulmonary capillary wedge pressure (not significant) and
right atrial pressure (not significant). End systolic wall stress
(p , 0.001) was lower in patients with AS than in patients
with DCM. There was a trend towards lower end diastolic
wall stress in patients with AS, although it never became
significant.
Myocardial cytokine gene expression in AS, DCM, and
normal hearts
As fig 1 shows, myocardial cytokine gene expression was
barely detectable in healthy controls. In patients with DCM
(p , 0.001) and in patients with AS (p , 0.001) myocardial
expression of TNFamRNA copies corrected for b actin mRNA
copies was increased compared with healthy donor hearts.
TNFa gene expression was significantly higher in patients
with aortic valve disease than in patients with idiopathic
DCM (p = 0.009). There were no differences between IL-1b
and IL-6 gene expression in both groups (fig 1). Myocardial
TNFa gene expression correlated significantly with IL-6 gene
expression (r = 0.619, p , 0.001) as well as with IL-1b gene
expression (r = 0.407, p = 0.017). Lastly, IL-1b correlated
with IL-6 gene expression (r = 0.487, p = 0.016).
Haemodynamic parameters and cytokine gene
expression
No correlation was noted between parameters of LV
contractile function such as LVEF, pulmonary capillary
wedge pressure, mean pulmonary artery pressure, right atrial
pressure, cardiac output, end diastolic wall stress, end systolic
wall stress, aortic valve area, and myocardial cytokine gene
expression of TNFa, IL-1b, and IL-6. Multivariate stepwise
analysis found that no variable was independently related to
TNFa formation in either the AS or in the DCM group.
However, myocardial gene expression of TNFa was signifi-
cantly higher in patients with well compensated AS than in
patients with decompensated AS (p = 0.017). Similarly,
patients with decompensated DCM were characterised by
significantly lower TNFa gene expression than were patients
with well compensated DCM (p = 0.011) (fig 2).
Table 1 Oligonucleotides
Length GC (%) Tm ( C˚)
TNFa
Primers
59-AAGAGTCCCCCAGGGACCTCM-39 21 61 53
59-CCTGGGAGTAGATGAGGTACA-39 21 52 49
Product 230 88.2
IL-6
Primers
59-CAGCTATGAACTCCTTCTCCACAAGC-39 26 50 64.8
59-CTGAGATGCCGTCGAGGATGTACCG-39 25 60 67.9
Product 201 85.5
b Actin
Primers
59-AGCACGGCATCGTCACCAACT-39 21 57.1 62.7
59-TGGCTGGGGTGTTGAAGGTCT-39 21 57.1 62.7
Product 180 86.0
Human cytokine coding genes (GenBank Accession Numbers: TNFa (M10988), IL-1b (M15330), IL-6 (M29150),
b actin (X00351).
IL, interleukin; Tm, melting temperature; TNFa, tumour necrosis factor a.
Table 2 Clinical characteristics
AS (n = 24) DCM (n = 10) p Value
Sex (men/women) 14/10 6/4 NS
Age (years) 70 (8) 56 (12) 0.001
NYHA class 2.2 (0.9) 2.6 (1.1) 0.030
BSA (m2) 1.81 (0.05) 1.94 (0.04) NS
Serum creatinine (mmol/l) 88 (18) 106 (35) NS
Serum blood urea (mmol/l) 8.2 (1.8) 14 (2.1) NS
Serum sodium (mmol/l) 142 (3) 143 (2) NS
White cell count (6109/l) 8 (2) 8 (3) NS
CRP (mg/l) 0.5 (0.1) 0.4 (0.2) NS
Medications
ACE-I or ARB 14% 27% NS
Diuretics 25% 65% 0.002
b Blockers 36% 24% NS
Digoxin 0% 0% NS
Data are mean (SD), number, or percentage.
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin I
receptor blocker; AS, aortic valve stenosis; BSA, body surface area; CRP,
C reactive protein; DCM, dilated cardiomyopathy; NS, not significant;
NYHA, New York Heart Association.
Table 3 Haemodynamic and echocardiographic
characteristics
AS (n = 24) DCM (n = 10) p Value
LVEDV (ml) 146 (11) 267 (21) ,0.001
LVESV (ml) 84 (14) 162 (18) 0.005
LVSP (mm Hg) 196 (24) 133 (23) ,0.001
RAP (mm Hg) 7 (1) 8 (1) NS
PAP mean (mm Hg) 28 (3) 26 (4) 0.070
PCWP (mm Hg) 19 (2) 17 (4) NS
Cardiac output (l) 4.94 (0.29) 5.19 (0.64) NS
LVEF (%) 56 (5) 37 (4) 0.013
ESWS (kdyn/cm2) 44 (7) 112 (11) ,0.001
EDWS (kdyn/cm2) 29 (17) 43 (9) 0.056
LVEDD (mm) 47 (6) 68 (6) 0.004
IVSd (mm) 13 (2) 12 (3) NS
AV area (cm2) 0.64 (0.06) NA NA
AV gradient (mm Hg) 51 (6) NA NA
Data are mean (SD).
AV, aortic valve; EDWS, end diastolic wall stress; ESWS, end systolic
wall stress; IVSd, interventricular septal thickness at end diastole; LVEDD,
left ventricular end diastolic diameter; LVEDV, left ventricular end
diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left
ventricular end systolic volume; LVSP, left ventricular systolic pressure;
NA, not applicable; PAP, pulmonary artery pressure; PCWP, pulmonary
capillary wedge pressure; RAP, right atrial pressure.
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Cytokine gene expression and circulating cytokine
concentrations in patients with AS
Circulating TNFa protein concentrations ranged from 2.64–
23.34 pg/ml (mean (SD) 5.64 (1.00) pg/ml), sTNFR1 ranged
from 744–2414 pg/m l (mean (SD) 1147 (96) pg/ml), sTNFR2
ranged from 822–3965 pg/ml (mean (SD) 2132 (196) pg/ml),
and IL-6 ranged from 0.58–34.20 pg/ml (mean (SD) 4.07
(1.66) pg/ml). As table 4 shows, TNFa, IL-6, sTNFR1, and
sTNFR2 were closely linked to each other. A strong inverse
relation was noted between TNFa protein and TNFa
(r = 20.685, p = 0.014) and IL-1b gene expression
(r = 20.664, p = 0.018) and between sTNFR2 and TNFa
gene expression (r = 20.685, p = 0.020).
DISCUSSION
The main findings in this study are the following. Firstly,
myocardial cytokine gene expression is upregulated in the
myocardium of both patients with AS and patients with DCM
compared with normal hearts, with significantly higher
upregulation of TNFa in AS than in DCM. Secondly, patients
with decompensated AS or DCM are characterised by a lower
TNFa gene expression than are patients with well compen-
sated heart failure. Thirdly, in patients with AS an inverse
correlation was noted between circulating TNFa concentra-
tions and TNFa gene expression. These data suggest that,
both in AS and in DCM, cytokine gene expression has an
adaptive role in LV remodelling.
Myocardial cytokine gene expression in AS and DCM
Previous experimental and human studies have shown that
cardiomyocytes themselves are an important producer of
relevant cytokines.12 25–27 Of note, TNFa is present in
immunodetectable concentrations in the cytosolic fraction
of human explanted failing myocytes and the TNFa gene is
upregulated in patients with chronic mitral regurgitation,
whereas neither TNFa protein nor TNFa gene expression is
elaborated in the heart under non-failing condition.4
Similarly we noticed a significant increase in TNFa, IL-1b,
and IL-6 expression in AS and DCM as compared with
healthy controls, suggesting that pressure overload and DCM
and the resultant stretch stimulus result in TNFa gene
expression.28 An interesting, albeit unexpected, finding was
that TNFa gene expression was two- to threefold higher in
patients with AS than in patients with DCM. The exact
reason why pressure overload results in a greater stimulus for
cytokine production in DCM is unknown. Nevertheless our
data are in accordance with those of Kapadia and collea-
gues,28 who reported higher TNFa and TNFa receptor plasma
concentrations in patients with pressure overload than in
patients with volume overload caused by mitral regurgitation.
Myocardial cytokine gene expression and LV
haemodynamic function
In contrast to previous studies that reported a relation
between filling pressures15 and TNFa gene expression, as well
as between wall stress and myocardial cytokine gene
expression,13 no such relation was detectable in the present
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Figure 1 Level of gene expression of tumour necrosis factor a (TNFa),
interleukin (IL) -6, and IL-1b in normal hearts, patients with dilated
cardiomyopathy (DCM), and patients with aortic valve stenosis (AS).
Numbers of copies of TNFa, IL-6, and IL-1b are indexed to a million
copies of b actin. *p , 0.05 v AS; **p , 0.001 v normal.
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Figure 2 Level of gene expression of TNFa in patients with
compensated and decompensated DCM (upper panel) and AS (lower
panel). Number of copies of TNFa is indexed to a million copies of b
actin.
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study. On the contrary, in patients with AS, we noticed high
TNFa mRNA concentrations despite normal LV systolic
function. The reasons for this discrepancy may be related to
differences in aetiology and the temporal stage of the heart
failure phenotype studied. Indeed, Torre-Amione and collea-
gues17 reported similar findings after orthotopic heart
transplantation. In routine surveillance endomyocardial
biopsies of transplant recipients with normal LV systolic
function and with no histological evidence of rejection, they
noticed upregulated TNFa gene expression.17 They speculated
that in accordance with transgenic mice overexpressing TNFa
the initial contractile function remains normal despite the
high cytokine concentrations, but that cellular abnormalities
are being created that will produce a cardiomyopathic state
over time. Thus, it appears that in these early stages the
expression of low concentrations of TNFa for relatively brief
periods of time may provide the heart with a short term
adaptive response to environmental stress, both by increasing
sarcomeric protein synthesis and by expressing heat shock
proteins in the cells.29 These observations may explain why, at
least in patients with AS, LV systolic function can adapt
despite high myocardial cytokine concentrations.
Myocardial cytokine gene expression in
decompensated heart failure
Although no correlation was noted between TNFa gene
expression and LV haemodynamic function in the whole
study population, patients with decompensated heart failure
in the AS and DCM groups had lower TNFa gene expression
than did patients with well compensated heart failure. It is
important to recognise that the design of this study does not
establish a clear cut cause and effect relation between altered
TNFa gene expression and the development of cardiac failure.
Indeed, it is likely that a variety of mechanisms contribute to
the observed change in myocyte phenotype. This statement
notwithstanding, it bears emphasising that our data corro-
borate previous studies that showed that altered myocardial
expression parallels LV deterioration. Firstly, after transaortic
constriction14 proinflammatory cytokine production rises
transiently and declines over time when heart failure
develops. Secondly, similar time dependent changes in
expression of other genes occur during the transition of
compensated to decompensated heart failure. Myocardial
inducible nitric oxide synthase is higher in patients with New
York Heart Association class II heart failure than in patients
with more advanced heart failure30 and growth factors such
as insulin-like growth factor and endothelin are known to be
upregulated in the early phase of hypertrophy but are no
longer detectable when wall stress increases.23 Although it is
likely that a variety of mechanisms contribute to the observed
change in myocyte phenotype, all these data indirectly raise
the intriguing possibility that load, and wall stress in
particular, is an important stimulus for cytokine gene
expression with high gene expression if wall stress is normal
but a blunted response whenever wall stress increases.
Circulating cytokines and gene expression
The relation between circulating cytokine concentrations and
myocardial cytokine production remains controversial.
Documented cardiac spillover as an explanation for high
TNFa concentrations has been called upon by some investi-
gators and refuted by others. Of note neither Munger et al31
nor Petretta et al32 found any significant difference between
plasma cytokine concentrations of arterial and coronary sinus
blood. On the other hand, Tsutamoto et al33 reported a
significant transmyocardial TNFa gradient in patients with
DCM.33 In patients with AS we observed an inverse
correlation between circulating TNFa and sTNFR2 concen-
trations and myocardial gene expression. Although Kapadia
et al28 never reported a similar correlation, Torre-Amione et al4
reported significantly lower TNFa concentrations in patients
with high myocardial TNFa concentrations. In addition
transgenic mice that overexpress TNFa have undetectable
peripheral TNFa concentrations.34 35 Although the exact
mechanism for this inverse relation is unknown, we
speculate that the circulating TNFa concentrations may act
as a negative feedback system that modulates myocardial
gene expression. Higher circulating TNFa results in lower
gene expression and vice versa.
Limitations
Firstly, because of the small sample size of endomyocardial
biopsies, we could establish the presence of cytokines in the
myocardium only by observing cytokine mRNA by reverse
transcription PCR and not by concomitant direct evidence in
the myocardium of the cytokine protein itself. This would
have provided definite proof of the myocardial presence of
the cytokine because of post-transcriptional modification of
cytokine protein translation. However, in a previous study
concordance between myocardial TNFa gene expression and
protein expression was reported. In the failing human heart,
TNFa immunostaining was detected in all biopsies in which
TNFa mRNA expression was inferred by reverse transcription
PCR.17 Secondly, it is well known that cytokine gene
expression is altered during extracorporeal circulation in a
time dependent matter. As it is impossible to obtain
percutaneous transvalvar endomyocardial biopsies from
patients with AS, we tried to avoid this bias by taking the
biopsy immediately after starting the pump run through the
excised aortic valve. By this approach the impact of
extracorporeal circulation upon gene expression could be
limited. Thirdly, mechanical forces may vary at different
layers of the ventricular wall and may affect gene
expression. To overcome this problem we did not take
biopsies from the right ventricle but in both patients with
AS and patients with DCM we took endomyocardial
biopsies at the level of the distal left interventricular
septum, which is subject to the sustained load. In addition
in patients with DCM, mRNA expression of TNFa did not
differ significantly between right ventricular and LV endo-
myocardial biopsies.36
Table 4 Correlations between serum cytokines in patients with AS
TNFa sTNFR1 sTNFR2 IL-6
r p Value r p Value r p Value r p Value
TNFa NA NA 0.710 ,0.001 0.645 0.002 0.479 0.033
sTNFR1 0.710 ,0.001 NA NA 0.872 ,0.001 0.783 ,0.001
sTNFR2 0.645 0.002 0.872 ,0.001 NA NA 0.612 0.004
IL-6 0.479 0.033 0.783 ,0.001 0.612 0.004 NA NA
sTNFR, soluble tumour necrosis factor receptor.
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Clinical implications and conclusion
Haemodynamic load (AS) modulates proinflammatory cyto-
kine gene expression in AS and DCM. Normal LV systolic
function, together with the high myocardial cytokine gene
expression, in patients with well compensated heart failure
suggests that cytokine gene expression may serve as a short
term adaptive response and initiate cardiac remodelling.
Therefore, wall stress induced TNFa production may be a
novel autocrine or paracrine mechanism for regulating
cardiac structure; treatments that selectively interfere with
the cytokine pathway may be used to modulate myocyte
structure in the failing heart. Further studies are needed to
address this concept.
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